Treatment - Page 16 of 471 Posts on Medivizor

Evaluating the effectiveness of combining low-intensity extracorporeal shock wave therapy with vacuum erectile device for the treatment of patients with diabetes and erectile dysfunction.

Posted by Medivizor on Dec 4, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with a vacuum erectile device (VED) for the treatment of patients with diabetes mellitus (DM) and erectile dysfunction (ED) who were unresponsive to phosphodiesterase-5 (PDE5) inhibitors. The data showed that Li-ESWT combined with...

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Posted by Medivizor on Dec 4, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma (MM) ineligible for a transplant. The data showed that first-line treatment should be based on daratumumab (Darzalex)-based regimens or the VRd regimen [bortezomib (V; Velcade), lenalidomide...

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Posted by Medivizor on Dec 4, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma. The data showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) was the best treatment regimen in significantly improving overall survival and survival without cancer worsening in these patients. Some...

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Posted by Medivizor on Dec 4, 2022 in Infertility | 0 comments

In a nutshell This study evaluated whether the administration of growth hormone (GH) improves endometrial function and reproductive outcomes in women undergoing in vitro fertilization (IVF) cycles. The data showed that GH administration significantly improved endometrial function and increased the live birth and clinical pregnancy rate in these...

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Posted by Medivizor on Dec 4, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Posted by Medivizor on Dec 4, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo)...

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

$Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.$

Posted by Medivizor on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

$Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.$

Posted by Medivizor on Nov 22, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...

Comparing the effects of different antidepressant therapies on depression symptoms in patients with Parkinson’s disease.

Posted by Medivizor on Nov 22, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study compared the effectiveness of different antidepressant therapies on depression in patients with Parkinson’s disease (PD). The data showed that escitalopram (Cipralex), pramipexole (Mirapex), and repetitive transcranial magnetic stimulation (rTMS) were more effective than routine treatment in these patients. After 4 weeks,...

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Posted by Medivizor on Nov 22, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with tiragolumab (MTIG7192A) as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The data showed that tiragolumab plus atezolizumab significantly improved the objective response rate and the survival without...

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Posted by Medivizor on Nov 22, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Posted by Medivizor on Nov 22, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the outcomes of single-pass versus multiple-pass during aquablation in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The data showed that treatment with multiple passes during aquablation improved the urinary outcomes compared to a single pass in these patients. Some...

Treatment Posts on Medivizor

Evaluating the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma ineligible for a transplant.

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Comparing the effects of different antidepressant therapies on depression symptoms in patients with Parkinson’s disease.

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Evaluating the outcomes of single-pass versus multiple-pass during aquablation in patients with urinary symptoms due to benign prostatic hyperplasia.

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email